Olivia Brown was six when her mother, Holly, first thought the child had heatstroke. Weakness and other signs led to tests. In June, an MRI showed a grade 3 medulloblastoma, a malignant brain tumour that is among the most common aggressive brain cancers in children. It later spread to her spine.

She had surgery to relieve pressure and remove tumour, then intensive chemotherapy and radiotherapy. Families are often given roughly even odds after that protocol. In June 2025 she was declared cancer-free. Holly had begun to plan the ritual that marks the end of treatment.

About six weeks later, in September 2025, scans showed the disease had returned. Holly expected another round of chemotherapy. Doctors told her there was no further curative option. The tumour had come back with a force that changed the goal of care from cure to comfort and time.

Medulloblastoma arises in the cerebellum or nearby structures and can seed along the spinal fluid. Standard treatment is surgery plus radiation and chemotherapy. Relapse after a clear scan is a known, feared path; recurrent disease is much harder to control. Some children live longer than first estimates when medicines for symptoms are adjusted. Reports from early 2026 said Olivia had been given a very short window in October, then improved somewhat after a change in medication. That is not the same as a new chance at cure.

Holly, a mother of four, has described the second diagnosis as a heart being torn out. She also describes a child who still laughs, plays, wears a tiara in hospital, eats ice cream, and sleeps with a doll. The photographs that travel with the story—hair before treatment, a shaved head and feeding-tube tape after it, a smile with a cone—are the ordinary life of a little girl interrupted twice.

There is no tidy ending in the public record. What remains is a parent making days count when medicine has said the days are limited, and a child who is still recognisably herself between appointments. Childhood brain tumours are rare; medulloblastoma is the one families hear about most. Relapse after an all-clear is why “cancer-free” is always provisional until years have passed.

Sources
UK reporting on Olivia Brown and Holly Brown (Daily Record, The Sun)
Cancer Research UK and clinical summaries of paediatric medulloblastoma and relapse after first-line treatment